Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)
Simon Couillard, William Il Hoon Do, Richard Beasley, Timothy S C Hinks, Ian D Pavord, Simon Couillard, William Il Hoon Do, Richard Beasley, Timothy S C Hinks, Ian D Pavord
Abstract
The prototype ORACLE scale based on two simple measures of type 2 airway inflammation (blood eosinophils and F ENO) quantifies the excess risk conferred by raised biomarkers that is removed by type-2 anti-inflammatory treatment in trial populations https://bit.ly/3F1gnUl.
Conflict of interest statement
Conflict of interest: S. Couillard received a nonrestricted research grant from Sanofi-Genzyme for investigator-initiated type 2 innovation research, and received speaker honoraria from GlaxoSmithKline, Sanofi-Regeneron and AstraZeneca; outside the submitted work. Conflict of interest: W.I.H. Do is cofounder and shareholder of the Albus Health company; outside the submitted work. Conflict of interest: R. Beasley has received honoraria for presentations or consulting in advisory boards from AstraZeneca, Asthma and Respiratory Foundation of New Zealand, Avillion, Cipla, and Theravance; and research grants from AstraZeneca, CureKids (NZ), Genentech and the Health Research Council of New Zealand. Conflict of interest: T.S.C. Hinks has received grants from the Wellcome Trust, The Guardians of the Beit Fellowship, Pfizer Inc., Kymab Ltd, University of Oxford, Sensyne Health and Sanofi Genzyme, outside the submitted work. He has received personal fees from AstraZeneca, TEVA, Omniprex and Peer Voice, outside the submitted work. Conflict of interest: I.D. Pavord, in the last 5 years, has received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine AB, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini, and GSK, and payments for organising educational events from AstraZeneca, GSK, Sanofi/Regeneron, and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi, and Knopp, and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, AstraZeneca, Teva, and Chiesi. He has received grants from Chiesi and Sanofi Genzyme. He is co-patent holder of the rights to the Leicester Cough Questionnaire, and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014–2015, he was an expert witness for a patent dispute involving AstraZeneca and Teva.
Copyright ©The authors 2022.
References
- Global Initiative for Asthma . Global Strategy for Asthma Management and Prevention (2021 update). Available from: .
- Couillard S, Laugerud A, Jabeen M, et al. . Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax 2022; 77: 199–202.
- Couillard S, Shrimanker R, Chaudhuri R, et al. . FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma. Am J Respir Crit Care Med 2021; 204: 731–734. doi:10.1164/rccm.202104-1040LE
- Pavord ID, Holliday M, Reddel HK, et al. . Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med 2020; 8: 671–680. doi:10.1016/S2213-2600(20)30053-9
- Lee LA, Bailes Z, Barnes N, et al. . Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021; 9: 69–84. doi:10.1016/S2213-2600(20)30389-1
- Shrimanker R, Keene O, Hynes G, et al. . Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med 2019; 200: 1308–1312. doi:10.1164/rccm.201903-0599LE
- Kraft M, Brusselle G, Mark FitzGerald J, et al. . Patient characteristics, biomarkers, and exacerbation risk in severe, uncontrolled asthma. Eur Respir J 2021; 58: 2100413. doi:10.1183/13993003.00413-2021
- Busse WW, Wenzel SE, Casale TB, et al. . Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post hoc analysis. Lancet Respir Med 2021; 9: 1165–1173. doi:10.1016/S2213-2600(21)00124-7
- Beasley R, Holliday M, Reddel HK, et al. . Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019; 380: 2020–2030. doi:10.1056/NEJMoa1901963
- Pavord ID, Korn S, Howarth P, et al. . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–659. doi:10.1016/S0140-6736(12)60988-X
- Castro M, Corren J, Pavord ID, et al. . Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486–2496. doi:10.1056/NEJMoa1804092
- Agusti A, Bel E, Thomas M, et al. . Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410–419. doi:10.1183/13993003.01359-2015
- Dweik RA, Boggs PB, Erzurum SC, et al. . An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602–615. doi:10.1164/rccm.9120-11ST
- Couillard S, Pavord I. Exhaled nitric oxide, blood eosinophils and the risk of asthma attacks in randomised clinical trials: a systemic review and meta-analysis of individual participant data. .
- Bonini M, Di Paolo M, Bagnasco D, et al. . Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev 2020; 29: 190137. doi:10.1183/16000617.0137-2019
Source: PubMed